PET/CT in Hodgkin Lymphoma: An Update

被引:20
作者
Al-Ibraheem, Akram [1 ,2 ]
Mottaghy, Felix M. [3 ,4 ,5 ,6 ]
Juweid, Malik E. [2 ]
机构
[1] King Hussein Canc Ctr, Dept Nucl Med, Amman, Jordan
[2] Univ Jordan, Dept Radiol & Nucl Med, Div Nucl Med, Amman, Jordan
[3] Rhein Westfal TH Aachen, Univ Hosp RWTH, Dept Nucl Med, D-52074 Aachen, Germany
[4] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldor, Maastricht Univ Med Ctr, Aachen, Germany
[5] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, Maastricht, Netherlands
[6] Rhein Westfal TH Aachen, Univ Hosp RWTH, Dept Nucl Med, Pauwelsstr 30, D-52074 Aachen, Germany
关键词
POSITRON-EMISSION-TOMOGRAPHY; RESPONSE-ADAPTED THERAPY; B-CELL LYMPHOMA; METABOLIC TUMOR VOLUME; INTERIM F-18-FDG PET; CONTRAST-ENHANCED CT; BONE-MARROW BIOPSY; FDG-PET; PHASE-II; PREDICTIVE-VALUE;
D O I
10.1053/j.semnuclmed.2022.10.006
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
18F-FDG-PET/CT is now an integral part of the workup and management of patients with Hodgkin's lymphoma (HL). PET/CT is currently routinely performed for staging and for response assessment at the end of treatment. Interim PET/CT is typically performed after 1-4 of 6-8 chemo/chemoimmunotherapy cycles </n> radiation for prognostication and poten-tial treatment escalation or de-escalation early in the course of therapy, a concept known as response-or risk-adapted treatment. Quantitative PET is an area of growing interest. Met-rics such as the standardized uptake value (SUV), metabolic tumor volume, total lesion gly-colysis, and their changes with treatment are being investigated as more reproducible and, potentially, more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value. This review highlights the most relevant applications of PET/CT in HL, its strengths and limitations, as well as recent efforts to implement PET/CT-based metrics as promising tools for precision medicine. Finally, the value of PET/CT for response assessment to immunotherapy is discussed.Semin Nucl Med 53:303-319 (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:303 / 319
页数:17
相关论文
共 104 条
[1]   FDG-PET/CT in Lymphoma: Where Do We Go Now? [J].
Al Tabaa, Yassine ;
Bailly, Clement ;
Kanoun, Salim .
CANCERS, 2021, 13 (20)
[2]   Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma [J].
Al-Ibraheem, Akram ;
Anwer, Farah ;
Juweid, Malik E. ;
Shagera, Qaid Ahmed ;
Khalaf, Aysar N. ;
Obeidat, Shahed ;
Mansour, Areen ;
Ma'koseh, Mohammad ;
Halahleh, Khalid ;
Jaradat, Imad ;
Almasri, Nidal ;
Mansour, Asem .
SCIENTIFIC REPORTS, 2022, 12 (01)
[3]   Targeting immune checkpoints in lymphoma [J].
Ansell, Stephen M. .
CURRENT OPINION IN HEMATOLOGY, 2015, 22 (04) :337-342
[4]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[5]   Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].
Armand, Philippe ;
Shipp, Margaret A. ;
Ribrag, Vincent ;
Michot, Jean-Marie ;
Zinzani, Pier Luigi ;
Kuruvilla, John ;
Snyder, Ellen S. ;
Ricart, Alejandro D. ;
Balakumaran, Arun ;
Rose, Shelonitda ;
Moskowitz, Craig H. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+
[6]   Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease [J].
Bangerter, M ;
Moog, F ;
Buchmann, I ;
Kotzerke, J ;
Griesshammer, M ;
Hafner, M ;
Elsner, K ;
Frickhofen, N ;
Reske, SN ;
Bergmann, L .
ANNALS OF ONCOLOGY, 1998, 9 (10) :1117-1122
[7]   End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma [J].
Barnes, J. A. ;
LaCasce, A. S. ;
Zukotynski, K. ;
Israel, D. ;
Feng, Y. ;
Neuberg, D. ;
Toomey, C. E. ;
Hochberg, E. P. ;
Canellos, G. P. ;
Abramson, J. S. .
ANNALS OF ONCOLOGY, 2011, 22 (04) :910-915
[8]   Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma [J].
Barrington, S. F. ;
MacKewn, J. E. ;
Schleyer, P. ;
Marsden, P. K. ;
Mikhaeel, N. G. ;
Qian, W. ;
Mouncey, P. ;
Patrick, P. ;
Popova, B. ;
Johnson, P. ;
Radford, J. ;
O'Doherty, M. J. .
ANNALS OF ONCOLOGY, 2011, 22 (03) :739-745
[9]   PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study [J].
Barrington, Sally F. ;
Kirkwood, Amy A. ;
Franceschetto, Antonella ;
Fulham, Michael J. ;
Roberts, Thomas H. ;
Almquist, Helen ;
Brun, Eva ;
Hjorthaug, Karin ;
Viney, Zaid N. ;
Pike, Lucy C. ;
Federico, Massimo ;
Luminari, Stefano ;
Radford, John ;
Trotman, Judith ;
Fossa, Alexander ;
Berkahn, Leanne ;
Molin, Daniel ;
D'Amore, Francesco ;
Sinclair, Donald A. ;
Smith, Paul ;
O'Doherty, Michael J. ;
Stevens, Lindsey ;
Johnson, Peter W. .
BLOOD, 2016, 127 (12) :1531-1538
[10]   Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].
Barrington, Sally F. ;
Mikhaeel, N. George ;
Kostakoglu, Lale ;
Meignan, Michel ;
Hutchings, Martin ;
Mueeller, Stefan P. ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Fisher, Richard I. ;
Trotman, Judith ;
Hoekstra, Otto S. ;
Hicks, Rodney J. ;
O'Doherty, Michael J. ;
Hustinx, Roland ;
Biggi, Alberto ;
Cheson, Bruce D. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+